Intranasal Pharmaceutical Composition for Migraine Treatment
Summary
The USPTO has published a patent application (US20260083693A1) for an intranasal pharmaceutical composition containing ibuprofen and ketoprofen for treating migraine and headaches. The application details a method for manufacturing preparations with a combination of these active ingredients at reduced dosages compared to oral administration.
What changed
This document is a published patent application from the USPTO detailing a novel intranasal pharmaceutical composition for the acute treatment of migraine and other forms of headache. The composition combines ibuprofen and ketoprofen at a fraction of the dose typically required for oral administration, aiming for enhanced efficacy and potentially reduced side effects. The application also covers the manufacturing method for preparations containing this combination.
While patent applications do not impose direct regulatory obligations on companies, they signal potential future market exclusivity for specific drug formulations and delivery methods. Companies involved in migraine treatment or drug delivery systems should monitor this application and related patents, as it may impact their own research, development, and commercialization strategies. The filing date was September 24, 2024, with publication anticipated on March 26, 2026.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PHARMACEUTICAL COMPOSITION FOR THE ACUTE TREATMENT OF MIGRAINE AND OTHER FORMS OF HEADACHE
Application US20260083693A1 Kind: A1 Mar 26, 2026
Inventors
Guillermo Antonio GARCIA PITTALUGA, Julio César VILLAMIL TORRES, Sankar SHANMUGAM, Camilo REY FERRO
Abstract
A pharmaceutical composition for intranasal administration and manufacturing method of preparations containing a combination of ibuprofen and ketoprofen at a fraction of the dose required when the same active ingredients are administered orally, useful in the treatment of migraine and other forms of headache.
CPC Classifications
A61K 31/192 A61K 9/0043 A61K 9/08 A61P 25/06
Filing Date
2024-09-24
Application No.
18894711
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.